Posted by Michael Wonder on 11 May 2021
Additional measures to allow experts to focus on COVID-19 activities
11 May 2021 - EMA is implementing additional temporary measures to further streamline activities in the European medicines regulatory network to enable experts to deal with an increasing volume of COVID-19-related assessment procedures.
Due to the very active pipeline of upcoming COVID-19 vaccines and treatments, a number of ongoing procedures, and the roll-out of authorised vaccines to millions of people across the EU, the resources of EMA and the European medicines regulatory network are highly focused on the review of COVID-19 vaccines and therapeutics, and the rigorous safety monitoring of these medicines.
